Putting the brakes on angiogenesis through a novel VEGF-KLH (kinoid) vaccine

Jayakumar R. Nair, Sanjay Bansal, Kelvin P. Lee

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Angiogenesis, the growth of new blood vessels, is essential for tumor growth and metastasis. Of the several known angiogenic factors, VEGF is an important mediator of tumor-induced angiogenesis and represents a potential target for innovative anticancer therapy. Recently, humanized monoclonal anti-VEGF antibody (bevacizumab) has been approved by the US FDA for combinatorial therapies with cytotoxic drugs in metastatic colorectal cancer. However, adverse side effects and enormous costs are associated with the use and delivery of bevacizumab. In the study under evaluation, Rad et al. demonstrated an alternative approach by using active immunization in mice with a novel VEGF-kinoid vaccine. The authors observed that the antitumor effects elicited by their vaccine were as effective as bevacizumab in xenografted-tumor mouse models.

Original languageEnglish (US)
Pages (from-to)491-496
Number of pages6
JournalExpert Review of Vaccines
Volume6
Issue number4
DOIs
StatePublished - Aug 1 2007

Keywords

  • Angiogenesis
  • Bevacizumab
  • Immunotherapy
  • Kinoid
  • Metastasis
  • VEGF-KLH

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Putting the brakes on angiogenesis through a novel VEGF-KLH (kinoid) vaccine'. Together they form a unique fingerprint.

Cite this